The clonogenic cells of chronic myeloid leukaemia (CML), unlike normal haemopoietic colony forming cells (CFC), are resistant to the growth inhibitory effects of the chemokine, macrophage inflammatory protein-1␣ (MIP-1␣). Here, we tested the hypothesis that MIP-1␣ protects normal, but not CML, CFC from the cytotoxic effects of the cell-cycle active drug cytosine arabinoside (Ara-C). Using a 24-h Ara-C protection assay we showed that MIP-1␣ confers protection to normal CFC but also sensitises CML CFC to Ara-C. The differential MIP-1␣ responsiveness was not due to a down-regulation of MIP-1␣ receptors on CML CD34
Introduction
Chemokines are a family of 8-to 10-kDa proteins with 20 to 70% homology in amino acid sequences. Over 40 different members have been identified to date and their structural and biological properties have been reviewed in a number of recent articles. [1] [2] [3] Chemokines can be subdivided into at least four different subfamilies on the basis of the relative position of their cysteine residues. 1 The largest families are the ␣ and ␤ chemokines, the latter being characterised by two adjacent cysteine residues (cysteine-cysteine) thus also designated CCchemokines. 1 Chemokines are produced by an array of stromal cell types including endothelial cells, 4 macrophages 5 and fibroblasts 6 in response to pro-inflammatory stimuli. 7 Members of the chemokine family have distinct but overlapping biological activities that include the regulation of leukocyte trafficking, 8, 9 modulation of tumour growth 10 and angiogenesis. 11, 12 Also, some of these chemokines, including the CCchemokine macrophage inflammatory protein-1␣ (MIP-1␣), have direct growth inhibitory effects on haemopoietic progenitor cells in vivo [13] [14] [15] and in vitro. 16, 17 Chemokines elicit their effects on cells via G protein-coupled proteins. 2 To date, at least nine human CC chemokine receptors (CCR-1 to CCR-9) have been identified 2, 10, 18 and four of those (CCR-1, 3, 4 and 5) have been reported to bind MIP-1␣. [18] [19] [20] [21] [22] [23] [24] It is as yet unknown which receptor(s) elicit(s) the growth inhibitory effect of MIP-1␣ on haemopoietic progenitor cells.
The growth suppressive effect of MIP-1␣ is not observed in primitive progenitor cells from patients with chronic myeloid leukaemia (CML), 25, 26 an acquired clonal haemopoietic stem cell disease characterised by the 9:22 translocation which results in the expression of the bcr/abl protein tyrosine kinase (PTK). 27 The abrogation of MIP-1␣ responses in Ph + cells may provide a rationale for the treatment of CML patients and in vitro purging strategies in that, compared to normal cells, these leukaemic cells will not be protected from cell cycle specific cytotoxic drugs. 27 It has recently been shown that the lack of MIP-1␣ responsiveness in CML cannot be explained by the absence of MIP-1␣ receptors on CML CD34
+ cells. 26 This suggests that the coupling between MIP-1␣ receptor binding and signalling for growth inhibition must be dysfunctional. Thus, a possible explanation for the aberrant response to MIP-1␣ is that it occurs as a consequence of bcr/abl PTK expression in CML haemopoietic progenitor cells. In the present study we investigated the effects of BB10010, a nonaggregating variant of the human MIP-1␣ molecule, 28 on haemopoietic progenitor cells isolated from CML patients in the chronic phase of the disease. We confirmed, that the clonogenic cells in CML, unlike normal haemopoietic progenitor cells, are refractory to the cell cycle inhibitory effects of MIP-1␣. 25 We then extended this finding to a 24 h druginduced cell death assay and demonstrated that MIP-1␣ confers protection to normal but sensitises CML clonogenic cells to the cytotoxic effects of cytosine arabinoside (Ara-C). The lack of MIP-1␣-responsiveness in CML could not be attributed to receptor down-modulation as receptor levels were similar in normal and CML CD34 + cells. Thus, the aberrant MIP-1␣ response in CML haemopoietic cells appears to be due to defects in the signal transduction pathways downstream of the MIP-1␣ receptors. A normal adhesion response to MIP-1␣ in CML CD34
+ cells suggests the presence of functional MIP-1␣ receptors and indicates that MIP-1␣ signalling pathways are not completely uncoupled in CML cells.
Materials and methods

Long-term bone marrow cultures (LTBMC) and cell cycle analysis by thymidine suicide assays
After separation from red cells using methylcellulose, 2 × 10 7 MNC (mononuclear cells) (BM) in 10 ml of LTBMC medium were added to 25 cm 2 tissue culture flasks (Falcon; Becton Dickinson, San Jose, CA, USA). 29 Each 10 ml of LTBMC medium consisted of 1 ml FCS, 1 ml HS, 7.9 ml of IMDM (350 mOsm/kg) and 0.1 ml of 5 × 10 −5 M hydrocortisone succinate (Sigma, Poole, UK). After inoculation, the flasks were gassed with 5% carbon dioxide in air, then capped and incubated at 33°C. Cultures were fed routinely on a weekly basis by replacing half the volume of supernatant with fresh medium. After reaching confluency (usually 3-4 weeks after inoculation) LTBMC were irradiated at 15 Gy on a linear accelerator to destroy endogenous haemopoiesis and recharged within 24 h with 1 to 2 × 10 6 fresh MNC/flask isolated either from normal allogenic bone marrow donors, umbilical cord blood or CML patients. After 7 days incubation at 33°C half of the culture medium was removed and replaced with fresh medium with or without the non-aggregating variant of MIP-1␣, BB10010 (British Biotech, Oxford, UK; 100 ng/ml). On day 8-9 the adherent layers (AL) were trypsinised and the resulting single cell suspensions were subjected to plastic adherence to remove stromal elements. The cell cycle status of the AL-haemopoietic progenitor cells (AL HPC) was then analysed using a standard thymidine suicide assay as previously described. 29 Briefly, each sample was divided into two and incubated with or without 100 Ci 3 H-thymidine (DuPont, Boston, MA, USA) for 30 min at 37°C. The cell suspensions were washed twice with cold IMDM containing 100 g/ml cold thymidine (Sigma) and then plated at appropriate cell numbers in colony-forming cell assays. At day 14, cultures were assessed for the presence of colonies derived from burst-forming units-erythroid (BFU-E) and colony-forming cells-granulocyte/macrophage (CFC-GM). Percent kill of CFC was calculated as: [1 − (CFC number in 3 Hthymidine exposed cultures/CFC number in control cultures)] × 100. Endogenous MIP-1␣ levels in 3-4-week-old normal and CML LTBMC supernatants were determined using a commercially available ELISA (Quantikine human MIP-1␣, R&D Systems, Abingdon, UK) according to the manufacturer's instructions.
Cytogenetic studies
Conventional cytogenetic methods were used to obtain metaphase spreads of marrow aspirates or peripheral blood samples. Preparations were Giemsa banded before analysis. In some cases where conventional analyses failed due to a low mitotic index of the preparations the diagnosis of CML was confirmed on interphase cells using fluorescent in situ hybridisation (FISH) employing a bcr/abl specific probe (Vysis, Downers Grove, USA). FISH studies were performed according to the manufacturer's instructions and slides were analysed using a Zeiss Axioskop fluorescence microscope.
Isolation of mononuclear and CD34
+ cells
All samples were taken with appropriate informed consent from the patients according to institutional guidelines. Blood and bone marrow samples were collected in sterile tubes containing preservative-free heparin and the mononuclear cells (MNC) were isolated by centrifugation on Ficoll-Hypaque (Lymphoprep, 1.077 g/ml, Nycomed; Birmingham, UK) at 400 g for 25 min. The MNC at the interface were collected and washed in PBS containing 0.5% (w/v) BSA. CD34 + cells from normal bone marrow (BM) (NBM CD34 + cells, n = 10), patients with CML (CML CD34 + cells, n = 33; clinical characteristics are shown in Table 1 ) and patients undergoing peripheral stem cell collections (n = 18; 8 multiple myelomas, 2 teratomas, 1 sarcoma, 4 non-Hodgkin lymphomas, 1 chronic lymphocytic leukaemia, 1 breast cancer and 1 acute lymphatic leukemia) were isolated using the Mini-MACS immunomagnetic separation system (Miltenyi Biotec, Bergisch Glad- bach, Germany) according to the manufacturer's instructions. Briefly, 10 8 cells were suspended in 300 l of sorting buffer (PBS supplemented with 5 mM EDTA and 0.5% (w/v) BSA) and incubated with 100 l human IgG to block Fc receptors (8 mg/ml) and 100 l monoclonal microbead-conjugated CD34 antibody (clone QBEND/10; Miltenyi Biotec) for 30 min at 4°C. Thereafter the cells were washed and passed through a 30-m nylon mesh and separated in a column exposed to the magnetic field of the MACS device. The column was washed four times with sorting buffer (500 l aliquots) and removed from the separator. The retained cells were eluted in 1 ml sorting buffer and counted using a haemocytometer.
h cytosine arabinoside protection assay
Aliquots of 10 6 MNC were resuspended in 1 ml of Iscove's modified Dulbeccos medium (IMDM) (320 mOsm/kg) and incubated in 5 ml polyethylene tubes (Falcon, Becton Dickinson) with or without MIP-1␣ (150 ng/ml) for 2 h at 37°C before addition of various concentrations of freshly reconstituted cytosine arabinoside in PBS (Ara-C, Sigma, final concentrations 10 −9 to 10 −6 M). Suspension cultures were then incubated for 24 h at 37°C in 5% CO 2 and 5% O 2 in nitrogen. Thereafter, cells were washed twice in PBS and the number of colony forming cells assessed in soft gel assays. On day 14 the total colony numbers (CFC-GM and BFU-E) in MIP-1␣ treated and untreated cultures were expressed as percent of the respective controls.
Similar studies were also performed on purified NBM and CML CD34
+ cells. However, due to limited cell numbers only a single Ara-C concentration (5 × 10 −7 M) which was selected on the basis of the described dose response experiments was used. 0.5 to 1 × 10 6 CD34 + cells freshly recovered from the MACS column were resuspended in 4 ml of IMDM/15% (v/v) FCS, split into four identical 1 ml aliquots and assigned to the following treatment groups: medium only control, MIP-1␣ control (150 ng/ml), Ara-C only (5 × 10 −7 M) and Ara-C + MIP-1␣. The cell suspensions were incubated in 24 well plates (Falcon, Becton Dickinson) and otherwise as described for the MNC experiments. After 24 h cells were pipetted into 5 ml polyethylene tubes, washed twice in PBS and viable cell numbers were determined using the trypan blue method in a haemocytometer. Aliquots of the four treatment groups were plated in colony forming cell assays (usually 2-3 × 10 3 CD34
+ cells). Results were expressed as the total number of CFC (CFC-GM and BFU-E) as percent of the untreated controls.
Immunophenotypical analysis of MIP-1␣ receptor expression on CD34
MIP-1␣ receptor expression on CD34
+ cells was analysed using the commercially available FluorokineTM hu MIP-1␣ receptor kit (R&D Systems) according to the manufacturer's instructions. Briefly, MACS purified CD34 + cells were washed and labelled with human MIP-1␣ biotin conjugate for 1 h at 4°C. Avidin-fluorescein and directly conjugated CD34-PE (HPCA-2, Becton Dickinson) were added and the cell suspension was further incubated at 4°C for 30 min. Subsequently, the cells were washed and fixed in 1% (v/v) formaldehyde. Receptor expression was analysed in a uniformly set gate comprising lymphoblast-like cells expressing the CD34 antigen. Results are expressed as the percentage of MIP-1␣ receptor positive cells in the CD34
+ cell population. The specificity of the MIP-1␣ receptor labelling was tested using a blocking antibody (R&D Systems) in combination with MIP-1␣ biotin or using a non-specific biotinylated protein (soybean trypsin inhibitor) as a negative control as described by the manufacturer. To check the specificity of MIP-1␣ binding two controls were used. Either the biotinylated MIP-1␣ binding could be competed off the cells by use of an excess of unlabelled MIP-1␣ or a specific blocking antibody to MIP-1␣ could be used to reduce the number of cells stained with the biotinylated MIP-1␣ to Ͻ1%. Flow-cytometric analysis was performed on a FACScan flow cytometer (Becton Dickinson) equipped with an argon-ion laser tuned at 488 nm within 24 h of sample processing.
Immunophenotypical analysis CCR-5 expression on CD34
+ cells 
FACS sorting of CD34
Immunomagnetically isolated CD34 + cells were sorted under sterile conditions into MIP-1␣ receptor positive and negative fractions on a FACS Vantage flow cytometer (Becton Dickinson). 2-3 × 10 3 cells of each fraction were plated into CFC assays and analysed for the presence of CFC-GM and BFU-E as previously described. 29 
Colony-forming cell assays
2-3 × 10 3 CD34 + cells or 0.5-1 × 10 5 MNC were plated as previously described. 29 Briefly, cells were added to a 1 ml mixture of 30% (v/v) foetal calf serum (FCS), 10% (w/v) deionized BSA, 10% (v/v) 5637-conditioned medium, 2 units erythropoietin and 1.35% (w/v) methylcellulose. After thorough mixing, cells were plated in triplicate and incubated for 14 days at 37°C in 5% CO 2 and 5% O 2 in nitrogen. Colonies of granulocyte-macrophage cells (CFC-GM) or erythroid cells (BFU-E) were assessed using standard criteria after 14 days' incubation.
Cell adhesion assay
Adhesion assays were performed in 96-well flat bottom microtiter plates (Costar, Cambridge, MA, USA) as previously described 30 with minor modifications. Briefly, wells were coated for 60 min at room temperature with 50 l aliquots of human fibronectin (Sigma) at 50 g/ml in PBS, and nonspecific binding sites blocked with 50 l of 10 mg/ml heatdenatured BSA. CD34 + cells were re-suspended at 1.5 × 10 6 /ml in serum-free medium (IMDM; Gibco Laboratories, Grand Island, NY, USA). 100 l aliquots of cell suspensions were then added to the wells in duplicate in the presence of various doses of MIP-1␣ (BB10010, British Biotech) The wells were incubated for 60 min at 37°C in a CO 2 incubator. Non-adherent cells were removed by shaking the plates horizontally on an electronic shaker set at 100 excursions/minute for 30 s and washing twice with 100 l PBS. Bound cells were removed by aspiration with PBS. Both fractions were counted with a haemocytometer and adhesion expressed as percentage of bound cells/(unbound + bound cells). Aliquots of each fraction (containing 2-3 × 10 3 cells) were also plated in CFC assays and the percentage of adhering colonies of granulocyte-macrophage cells (CFC-GM) and erythroid cells (BFU-E) were assessed using standard criteria after 14 days' incubation.
Statistical analysis
Data are expressed as mean ± s.e.m. Statistical significance was determined using the nonparametric Wilcoxon test for paired samples. The Kruskal-Wallis test was used to compare differences in MIP-1␣ receptor expression between NBM, LP and CML CD34 + cells.
Results
Cell cycle analysis of normal and CML colonyforming cells: effects of MIP-1␣
MNC isolated from normal individuals and CML patients were coincubated with pre-established irradiated LTBMC stromal layers and exposed to MIP-1␣ at 100 ng/ml for 24-48 h. We used MIP-1␣ at 100 ng/ml since our own unpublished results and other's previous studies 25 had shown lower concentrations to be ineffective with regard to cell cycle inhibition of normal colony-forming cells (CFC). Endogenous MIP-1␣ protein levels in primary normal and CML LTBMC supernatants were 14.3 ± 4.5 (n = 7) and 19.8 ± 8.5 pg/ml (n = 4; mean ± s.e.m., P Ͼ 0.05), respectively as determined by ELISA.
In pooled results from cultures initiated with normal bone marrow (n = 6) or umbilical cord blood (n = 3) cells, MIP-1␣ was found to block the ability of fresh medium to stimulate the entry of CFC into S phase (Figure 1a) . In contrast, under the same culture conditions the cell cycle status of CML CFC (n = 5) remained unchanged (Figure 1b) .
Figure 1
Differential effects of MIP-1␣ on the cell cycle status of normal (a) and CML haemopoietic progenitor cells (b). Mononuclear cells were isolated from NBM (n = 6) and CB (n = 3) and CML patients (n = 5) in chronic phase of the disease and seeded on pre-established irradiated long-term culture stroma layers. After 7 days of incubation at 33°C, half of the culture medium was removed and replaced with fresh medium with or without MIP-1␣ (100 ng/ml). On day 8-9, the cell cycle status of the stroma-adherent progenitor cells was analysed using a standard thymidine suicide assay as described in Materials and methods. The percentages of cells in S phase (mean ± s.e.m.) were calculated from assays in which the number of colonies (per 10 5 cells plated) counted in the normal controls (no 
Effect of MIP-1␣ on the Ara-C response of normal and CML CFC
MNC from normal donors and CML patients were incubated with or without MIP-1␣ (150 ng/ml) in the presence of various concentrations of Ara-C. Figure 2 shows that in the absence of MIP-1␣, the survival of both normal and CML CFC is similar (P Ͼ 0.05). In contrast, when MIP-1␣ was added to the cultures, significant differences in the Ara-C became evident: MIP-1␣ conferred protection to normal CFC-GM and BFU-E (Figure 2a and b, P Ͻ 0.05) , whereas the Ara-C dose response of CML CFC remained unchanged (Figure 2a and b) .
In a second set of experiments purified CD34 + cells were used to minimise potential effects of accessory cells. Ara-C treatment (5 × 10 −7 M) for 24 h significantly reduced the total number of viable nucleated cells in comparison to normal and CML control cultures. In contrast, MIP-1␣ alone did not have a cytotoxic effect either on normal or leukaemic CD34 + cells (data not shown). Figure 3 shows the results for the survival of CFC in the same cultures. In line with the total CD34
+ cell population experiments Ara-C treatment at 5 × 10 −7 M reduced the number of normal and CML CFC-GM and BFU-E to 52.2 ± 6.9, 46.3 ± 9.3 and 53.0 ± 11.8 and 34.6 ± 6.2% (mean ± s.e.m.) of the respective controls ( Figure 3 , P Ͻ 0.05). Differences in CFC survival in response to Ara-C between CML and normal cultures were not statistically significant and a 24 h exposure to MIP-1␣ alone did not alter the colony numbers generated from normal and leukaemic CD34 + cells (P Ͼ 0.
05). CFC-GM and BFU-E survival in normal CD34
+ cultures exposed to Ara-C was higher in the presence of MIP-1␣ than in the controls, although differences did not reach statistical significance. In contrast, CFC survival (CFC-GM and BFU-E) in Ara-C-treated leukaemic cultures was significantly lower in the presence than in the absence of MIP-1␣ (Figure 3 ). This
Figure 2
MIP-1␣ protects normal, but not CML, CFC from the cytotoxic effects of cytosine arabinoside. MNC isolated from NBM (n = 6) and CML BM or pB (n = 10) were cultured for 24 h at 37°C in the presence or absence of MIP-1␣ (150 ng/ml) and varying concentrations of Ara-C. Thereafter, cells were washed and plated in CFC assays. At day 14 the number of colonies derived from CFC-GM (a) and BFU-E (b) were counted and the results were expressed as CFC survival as the percentage of the respective controls. The total numbers (per 10 5 MNC plated) of CFC-GM and BFU-E in normal MIP-1␣ treated and untreated controls were 17 ± 4 and 142 ± 34, respectively. finding suggests a MIP-1␣-induced sensitisation of CML CFC to the cytotoxic Ara-C effect. Importantly, differences in the Ara-C response between normal and CML CFC became significant in the presence of MIP-1␣ (Figure 3 ; P Ͻ 0.05).
Two-colour immunofluorescence analysis of CD34
+ cells for MIP-1␣ receptor expression
The co-expression of the CD34 antigen and MIP-1␣ receptors was assessed on cells isolated from the bone marrow and peripheral blood (PB) of CML patients and compared to normal CD34 + cells obtained from LP and NBM. MIP-1␣ receptor expression was quantified as the percentage of MIP-R + cells in the CD34
+ population as shown in Figure 4 . The majority of CD34
+ cells expressed MIP-1␣ receptors and no significant differences were observed between the four groups (P Ͼ 0.05; Figure 5 ). None of the patient characteristics including the quality of the apheresis product (CFC-GM and CD34 + cell content) and the extent of pre-treatment with radio/ chemotherapy appeared to correlate with MIP-1␣ receptor expression on the isolated CD34 + cells in the LP samples (data not shown).
Functional properties of MIP-1␣ receptor positive and negative normal and CML CD34
The clonogenic potential of MIP-1␣ receptor positive (R + ) and
+ cells is shown in Table 2 . In general, CFC-GM and BFU-E were evenly distributed between the two cell fractions and this pattern was similar in both normal and CML CD34
+ cell populations.
Characterisation of the MIP-1␣ receptor subtype CCR-5 expressed by CD34 + cells
Only a small subset of CD34 + cells was found to coexpress CCR-5 (Table 3) and there were no significant differences between normal and CML CD34 + cell populations.
Effects of TNF-␣ on the expression of MIP-1␣ receptors
To determine whether TNF-␣ could upmodulate MIP-1␣ receptor expression by CML CD34 + cells as recently described by our group for LP CD34 + cells, 31 CD34 + cells were cultured in the presence of TNF-␣ (2 ng/ml) and subsequently analysed by flow cytometry. Figure 6a and b show that TNF-␣ effectively increased MIP-1␣ receptor levels on both CML CD34 + and LP CD34
+ cells, suggesting a normal regulatory response in CML cells.
Adhesion of normal and CML CD34 + cells to fibronectin; effect of MIP-1␣
CML and normal CD34 + cells suspended in serum-free medium attached efficiently to fibronectin (Figure 7) . At the end of a 60-min incubation at 37°C similar numbers of NBM CD34 + (54.4%) and CML CD34 + (51.2%) cells were found to adhere to fibronectin (Figure 7a and c, P Ͼ 0.05). In contrast, CFC-GM and BFU-E derived from CML CD34 + cells showed a significantly decreased adhesion when compared to their normal counterparts (Figure 7b and d, P Ͻ 0.05) , suggesting a potentially selective impairment in the adhesive capacity of MIP-1␣ sensitises CML CD34 + cells to Ara-C. NBM (n = 8) and CML CD34
+ cells (n = 10) were incubated in IMDM/15% FCS (v/v) at 37°C for 4 h in the absence or presence of MIP-1␣ (150 ng/ml). Thereafter, Ara-C (5 × 10 −7 M) was added and the cultures were further incubated for 24 h. Cells were washed and aliquots of the indicated treatment groups plated in CFC assays. After 14 days the total numbers of colonies derived from CFC-GM and BFU-E in the respective cultures was determined and the results were expressed as colony survival as a percent (mean ± s.e.m.) of the respective controls. *Denotes significant differences between CML and NBM CD34 + cells treated with the combination of Ara-C and MIP-1␣ (P Ͻ 0.05); # denotes significant differences between CML CD34
+ cells treated with Ara-C with or without MIP-1␣ (P Ͻ 0.05).
CFC within the CML CD34
+ populations. However, MIP-1␣ increased the number of adherent cells in both normal and CML CD34
+ cells (Figure 7 , P Ͻ 0.05) and this effect was observed irrespective of whether total cell counts or adherence of CFC was used as a read out of the assay system. Again, absolute numbers of adherent CFC were higher in the normal CD34 + cell population but relative increases over baseline control values were similar in both groups.
Discussion
In the present study we investigated the biological responsiveness of CML haemopoietic progenitor cells to the growth inhibitory chemokine MIP-1␣. Using a two-stage long-term bone marrow culture system and a standard thymidine suicide assay we showed that the clonogenic cells of CML, unlike normal haemopoietic progenitor cells, are refractory to the cell cycle inhibitory effects of MIP-1␣. This finding confirms previous experiments 25 and our own results obtained in a murine v-abl transfected stem cell model. 32 Based on these observations we next tested the hypothesis that MIP-1␣ can selectively protect normal haemopoietic progenitor cells whilst maintaining (or even increasing) the sensitivity of leukaemic cells to cell-cycle active chemotherapeutic drugs. To this end we developed a 24 h Ara-C protection assay. Ara-C was selected because of its relative cytotoxic specificity for S phase cells, 33 its confirmed efficacy in the treatment of CML, 34 and as an in vitro purging reagent. 35 Furthermore, in vitro studies 36 and preliminary clinical experience 37 suggest a preferential cytotoxic Ara-C effect on CFC GM from CML patients in chronic phase of the disease as compared to haemopoietic progenitors from normal subjects. This selective effect was observed particularly under experimental conditions involving prolonged exposure of haemopoietic progenitor cells to low concentrations of Ara-C. 36, 37 In contrast, our dose response studies with a 24 h exposure, on mononuclear cell preparations from normal individuals and CML patients revealed similar sensitivity to Ara-C in the absence of MIP-1␣. However, when MIP-1␣ was added to the suspension cultures a significant protection of normal CFC-GM and to a lesser extent BFU-E was observed whereas this effect was not observed using CML haemopoietic progenitor cells.
To eliminate potential effects of accessory cells similar experiments were performed using immunomagnetically purified CD34
+ cell populations. From the MNC experiments we determined that approximately 50% of the haemopoietic cells were killed at a Ara-C concentration of 5 × 10 −7 M, we therefore used this concentration to assess the effects of MIP-1␣ on Ara-C-induced CD34 + cell death. It is also worth mentioning that this Ara-C concentration is in the range observed in the plasma of patients receiving the drug in the course of standard chemotherapy protocols. 38 Several points were raised by these experiments. Firstly, a 24 h exposure to MIP-1␣ alone did not inhibit the growth of either normal or CML CD34 + cells as determined by viable cell counts or the formation of colonies in soft gel assays. These observations are not surprising in the case of CML haemopoietic progenitor cells as previous studies have shown the absence of MIP-1␣-induced growth inhibition. 25, 26 However, our own and others' findings in clonogenic and 3 H-thymidine incorporation assays 26 have established a dose-dependent inhibitory MIP-1␣ effect on normal CD34
+ cells from a variety of sources including cord blood, normal bone marrow 17, 39 and leukapheresis products. The direct growth inhibitory action of MIP-1␣ on normal haemopoietic progenitor cells appears to depend on the presence of several stimulating growth factors in the cultures. 17 Indeed, studies by Bonnet et al 40 suggest that MIP-1␣-induced growth inhibition of normal bone marrow CD34 + cells in suspension cultures supplemented with seven different haemopoietic growth factors may be detectable as early as 20 h after the addition of MIP-1␣. In contrast, our Ara-C-induced cell death assay did contain serum but no additional haemopoietic growth factors. This may account for the lack of MIP-1␣-induced growth suppression observed under these conditions. Secondly, the MNC data indicate that MIP-1␣ conferred some degree of protection from the cytotoxic Ara-C effect to normal but not to CML progenitor cells.
Thirdly and most importantly, MIP-1␣ appeared to increase the sensitivity of CML haemopoietic progenitor cells to Ara-C. A trend towards sensitisation was even observed at the level of CD34
+ cell survival and differences reached statistical significance when CFC-GM and BFU-E numbers were evaluated. These data agree with our recently published findings in the vabl transfected FDCP-Mix cell line, 32 where MIP-1␣-induced sensitisation to Ara-C was strictly dependent on the overexpression of functional v-abl protein tyrosine kinase (PTK). Taken together these results suggest that the cytoprotective and growth inhibiting effects of MIP-1␣ on normal haemopoietic cells may be distinct biological activities of the chemo-
Figure 4
Flow cytometric analysis of isolated CML-pB CD34 + cells from a representative experiment; two-colour immunofluorescence staining with FITC-avidin-biotin-MIP-1␣ complex and PE-conjugated anti-CD34 monoclonal antibody. Control cells were stained with a non-specific biotinylated protein (soybean trypsin inhibitor) and irrelevant mouse monoclonal antibody conjugated to PE as described in Materials and methods. Gates for the analysis of MIP-1␣ receptor expression on CD34
+ are defined as shown: R1 = lymphocyte gate (a), R2 = CD34 + lymphocytes (b). MIP-1␣ receptor expression was assessed as the percentage of positive cells in R1 and R2. Negative controls (as stated) above were used to set the gate such that 99% of the negative control cells were in the negative quadrant. Typical sorting gates are indicated in (c):
MIP-R
+ and were set to include a strongly negative and positive fraction respectively. 
CD34
+ cells were sorted into MIP-1␣ receptor positive and negative fractions and plated in colony forming cell assays. The data are presented as the number of colonies formed per 2 × 10 3 cells plated, and expressed as mean ± s.e.m. of n independent experiments with triplicate determinations.
Table 3
Expression of the MIP-1␣ binding chemokine receptor CCR-5 by CML CD34
50.6 ± 7.5 4.0 ± 1.2 P value 0.09 0.3
Purified CD34 + cells were double-stained with either biotinylated MIP-1␣ or anti-CCR-5 antibodies and antibodies specific for the CD34 antigen. Results are expressed as the mean percentages (± s.e.m.) of CD34
+ cells co-expressing MIP-1␣ receptors and CCR-5, respectively. The two groups were compared using the Student's t-test for unpaired samples.
kine. The sensitisation to the effect of Ara-C in CML indicates an aberrant rather than an absent MIP-1␣ response in CML progenitor cells.
We next investigated whether the altered MIP-1␣ response in CML progenitor cells is due to MIP-1␣-receptor down-
Figure 5
Constitutive expression of MIP-1␣ receptors on human CD34
+ cells isolated from NBM, LP and the pB and BM of CML patients. Purified CD34
+ cells were double-stained with biotinylated MIP-1␣ and antibodies specific for the CD34 antigen. Results are expressed as the percentage of CD34
+ cells co-expressing MIP-1␣ receptors. Horizontal bars denote the median of n individual determinations. There were no significant differences between the four groups (P Ͻ 0.05).
modulation on CML CD34
+ cells. Using a biotinylated MIP-1␣ molecule we have previously shown that MIP-1␣ receptors are expressed on Ph + cells from patients with CML 41 although these cells were found to be non-responsive to the growthinhibitory effect of MIP-1␣. In the present study we extended these observations to a larger CML patient cohort and this allowed us to compare quantitatively the receptor expression on CML CD34
+ cells with normal bone marrow and leukapheresis product derived CD34 + cells. In line with previous results, 26, 32 the majority of CD34 + cells was found to coexpress MIP-1␣ receptors. Furthermore, there were no significant differences in overall receptor expression in the three groups. We then investigated whether MIP-1␣ receptor levels on CML CD34
+ cells can be modulated by the proinflammatory cytokine TNF-␣. In line with our own recently published data 31 we found that TNF-␣ increases the MIP-1␣ receptor expression on CML CD34
+ cells suggesting a normal regulatory response in these cells. Importantly, when highly purified FACS sorted MIP-1␣ receptor positive and negative CD34 + cell populations were plated in CFC assays, a similar distribution of colony forming cells was observed.
As the differential responsiveness of CML and normal haemopoietic CFC to MIP-1␣ may be caused by differences in expression of MIP-1␣ receptor subtypes, we used a specific antibody raised against the MIP-1␣ binding chemokine receptor CCR-5 to address this issue. Employing a two-colour flow cytometric method we showed that CCR-5 is expressed on a small subset of CD34 + cells and again no differences in the expression levels between normal and CML CD34
+ cells were noted. The receptor data also agree with our results in the abl PTK FDCP-Mix model, that the expression of abl PTK activity in FDCP-Mix cells does not influence the overall expression of MIP-1␣ receptors. 32 To further investigate potential defects in the coupling of MIP-1␣ receptors in CML cells to intracellular signal transduction cascades, we compared the effects of MIP-1␣ on the adhesion of CML and normal CD34 + cells to the extracellular matrix molecule fibronectin. 42 Recently, we and others have demonstrated that CD34 + cell adhesion to fibronectin coated plastic surfaces is mainly mediated by both ␣4␤1 and ␣5␤1
Figure 7
Adhesion of NBM (a and b) and CML CD34 + (c and d) cells to fibronectin (FN); effect of MIP-1␣. All adhesion experiments were performed in serum-free medium for 60 min at 37°C. Adhesion was quantified by counting the numbers of fibronectin adherent and nonadherent cells (a and c) and also by determining the total numbers of colonies (CFC-GM and BFU-E) generated from these cells in CFC assays (b and d). MIP-1␣ was directly added at the indicated concentration to the adhesion medium at the beginning of each assay. Results are means ± s.e.m. 0/BSA indicates attachment of CD34 + cells to BSA in the absence of MIP-1␣ which served as a control for non-specific cell binding. *Denotes significant difference (P Ͻ 0.05) between MIP-1␣ treated cells and the respective controls (FN, no MIP-1␣).
integrins and that the affinity of the integrins can be modulated by haemopoietic growth factors 30, 43 and chemokines including MIP-1␣ (Dü rig et al, unpublished results) . We now show that MIP-1␣ increases the adhesion of CML CD34 + cells and colony forming cells in a dose-dependent manner to fibronectin, as observed for CD34 + cells isolated from normal bone marrow. These findings are consistent with recent studies 44 where MIP-1␣, produced by bone marrow stromal cells in response to interferon-␣, mediated the increased adhesion of normal and CML CFC to bone marrow stroma. It is noteworthy, that no differences in adhesion between total numbers of normal and CML CD34 + cells were detected in the absence of MIP-1␣. In contrast, adhesion of CML CFC-GM and CML BFU-E was significantly lower than normal progenitor cells raising the possibility that the adhesion defect in this small series of CML samples was restricted to the colony forming cells within the CD34 + populations. As most investigators use either total cell numbers 45 or adhesion of CFC 44, 46 as a readout of their assay systems, the latter results may help explain differences in the interpretation of the effects of bcr/abl on integrin function. Recently, a direct link between the expression of p210bcr/abl and abnormal ␤1 integrin function has been established. 46 In an elegant series of experiments these investigators employed breakpoint specific antisense oligodeoxynucleotides (AS-ODN) to block the expression of p210bcr/abl and found that adhesion of CML progenitors to fibronectin could be partly restored. Furthermore and importantly, it was shown by the same authors that the AS-ODN mediated adhesion increase also correlates with a significant inhibition of CML progenitor cycling.
In conclusion, our data suggest that CML, unlike normal CFC, are refractory to the cell-cycle inhibitory effects of MIP-1␣. This lack of response to MIP-1␣ was not due to receptor down-modulation. However, MIP-1␣ binding to CML CFC resulted in an aberrant response in that CML CD34 + cells were sensitised to the cytotoxic effects of Ara-C whereas MIP-1␣ conferred protection to normal CFC. However, the normal adhesion response of CML CD34 + cells exposed to MIP-1␣ suggests that at least one MIP-1␣ signalling pathway in CML remains functional. Thus CML haemopoietic progenitor cells, v-abl and bcr/abl transfected cell lines could serve to further dissect the signal transduction pathways activated by MIP-1␣ and related chemokines.
MIP-1␣ has now entered clinical trials as a putative chemoprotectant, aimed at reducing the marrow toxicity of various cytotoxic regimens. [47] [48] [49] Clinical trials have already demonstrated the feasibility and safety of MIP-1␣ in the treatment of cancer patients. [47] [48] [49] [50] The data presented here suggest a role for MIP-1␣ not only in the high-dose chemotherapy setting but also as a potential adjunct in the treatment of patients with chronic phase CML receiving low dose Ara-C alone or in combination with interferon-␣.
